

May 29, 2014



Navidea Biopharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAV), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Thomas Tulip, President and Chief Business Officer, will participate at the Jefferies 2014 Global Healthcare Conference June 2-5, 2014 at the Grand Hyatt in New York City, NY. Dr. Tulip will present a Company update on Thursday, June 5, 2014 at 1:30 PM EDT.

Investors and the public are invited to listen to a live webcast of Dr. Tulip's presentation at <http://wsw.com/webcast/jeff82/NAV>. Following the conference, the webcast will be archived for approximately 30 days.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAV) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms, including NAV4694, NAV5001, Manocept™ and NAV1800 (RIGScan™), to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek® (technetium 99m tilmanocept) Injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
or
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.